Directorate Change

Synairgen plc
11 April 2006



11 April 2006

                                  SYNAIRGEN PLC

                                  Board changes


The Board of Synairgen, the drug discovery company focused on identifying and
out-licensing new pharmaceutical products which address the underlying causes of
asthma and chronic obstructive pulmonary disease ('COPD'), announces that it has
appointed Dr David Bruce Campbell as a non-executive director with immediate
effect. He replaces David Norwood who has today stepped down from the Board to
devote more time to IP2IPO Group plc.


Bruce Campbell (61) is currently non-executive Chairman of Proximagen
Neuroscience plc, Chief Scientific Officer and a director of IP2IPO Group plc, a
director of Modern Biosciences plc and a non-executive director of iQur Limited
and Proximagen Limited.


Formerly, Dr Campbell was Senior VP of International Development at Neurocrine
Biosciences, Inc. ('Neurocrine'). Prior to joining Neurocrine, Dr Campbell
worked for 27 years at Servier (United Kingdom), latterly as Scientific
Director. In addition, he has also been a director and European Chairman of the
Drug Information Association and a member of the European ICH Safety Working
Party. Dr Campbell is a visiting Professor in Pharmacology at King's College,
London.


There are no further disclosures to be made in accordance with Schedule 2(g) of
the AIM Rules.


Simon Shaw, Chairman, commented:

'We are delighted that Bruce is joining the Board of Synairgen. His extensive
international experience in pharmaceutical drug development will be valuable to
Synairgen at this exciting time in our development.


'On behalf of the Board, I would like to thank David Norwood for his help and
guidance as a non-executive director of Synairgen since its formation in late
2003.'


                                     -Ends-


For further information, please contact:

Synairgen
Richard Marsden, Managing Director                     Tel: [phone]

Hogarth Partnership
Melanie Toyne-Sewell / Georgina Briscoe                Tel: [phone]



                      This information is provided by RNS
            The company news service from the London Stock Exchange